Interestingly, the anticancer activity of several PP2A-activating drugs depends on their ability to interact with the endogenous PP2A inhibitor SET, an oncoprotein overexpressed in ~30% of AML patients and associated with poor outcome18,19. Here, PTPA is linked to acute myeloid leukemia.